Breaking Barriers in Leptomeningeal Disease: A SNO-ASCO Consensus Review on Clinical Trial Design and Basic Science Integration
Cet article présente les conclusions d'une réunion de consensus organisée par la "Society for Neuro-Oncology" et l'"American Society of Clinical Oncology" sur les meilleures pratiques en matière de recherche clinique pour les maladies leptoméningées (LMD) liées aux complications des cancers, notamment l'examen du rôle de l'industrie et des chercheurs fondamentaux dans les essais cliniques, la fourniture de recommandations pour améliorer la conception des essais cliniques et l'accélération du recrutement dans les essais cliniques de patients présentant une LMD
Leptomeningeal disease (LMD) is a devastating complication of cancer, and its incidence is rising. The inaugural LMD Think Tank Meeting took place in 2023 during the Society for Neuro-Oncology (SNO) and American Society of Clinical Oncology (ASCO) Central Nervous System (CNS) annual meeting, convening an international group of clinicians and scientists dedicated to understanding and treating LMD in a multidisciplinary fashion. While this meeting laid the foundation for a SNO/ASCO consensus review on the clinical management of LMD, the frequent exclusion of LMD patients from trials was identified as a clear and pervasive challenge. To address this gap, a follow up assembly convened in 2024 with a goal of developing a SNO/ASCO consensus on best practices for clinical research; this included addressing the role of industry and basic scientists in clinical trials, providing guidance for improved clinical trial design, and accelerating the enrollment of LMD patients into clinical trials. Academic-industry partnerships and multi-institutional collaborations are crucial to advance our understanding of LMD, expand treatment access, and ultimately, improve survival and quality of life for our patients.Leptomeningeal disease (LMD) is a devastating complication of cancer, and its incidence is increasing. The LMD Think Tank Meeting in 2023 during the Society for Neuro-Oncology (SNO) and American Society of Clinical Oncology (ASCO) Central Nervous System (CNS) annual meeting, took place where several doctors and scientists dedicated to understand these patients. While this meeting laid the foundation for a SNO/ASCO review on the clinical management to treat the patients, the exclusion of LMD patients from trials was identified as a challenge. To address this, a follow up assembly convened in 2024 with a goal of developing a SNO/ASCO consensus on best practices for clinical research; this included addressing the role of industry and basic scientists in studies, providing guidance for improved clinical trial design, and the enrollment patients into trials.
Neuro-Oncology , article en libre accès, 2026